A biotechnology company focused on developing cancer therapeutics.
Investment Insights
AI-generated insights about Curis, Inc. from various financial sources
Thursday, September 11, 2025
The CEO made his first-ever stock purchases, totaling around $700,000, just before a major FDA ruling, which is considered a very bullish and compelling signal of confidence.
Saturday, August 16, 2025
The CEO made his first-ever purchase of the stock ahead of expected clinical trial results or product launches, a highly bullish signal suggesting confidence in a positive outcome.
Thursday, September 11, 2025
The CEO made his first-ever stock purchases, totaling around $700,000, just before a major FDA ruling, which is considered a very bullish and compelling signal of confidence.
Saturday, August 16, 2025
The CEO made his first-ever purchase of the stock ahead of expected clinical trial results or product launches, a highly bullish signal suggesting confidence in a positive outcome.